Suppr超能文献

改良的肿瘤负荷、肝功能、全身炎症和肿瘤生物学评分联合预测肝癌切除术后的长期预后。

Modified integrated tumor burden, liver function, systemic inflammation, and tumor biology score to predict long-term outcomes after resection for hepatocellular carcinoma.

机构信息

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA; Department of Surgery, University of Verona, Verona, Italy.

出版信息

HPB (Oxford). 2023 Dec;25(12):1484-1493. doi: 10.1016/j.hpb.2023.07.901. Epub 2023 Jul 22.

Abstract

BACKGROUND

A preoperative predictive score for hepatocellular carcinoma (HCC) can help stratify patients who undergo resection relative to long-term outcomes and tailor treatment strategies.

METHODS

Patients who underwent curative-intent hepatectomy for HCC between 2000 and 2020 were identified from an international multi-institutional database. A risk score (mFIBA) was developed using an Eastern cohort and then validated using a Western cohort.

RESULTS

Among 957 patients, 443 and 514 patients were included from the Eastern and Western cohorts, respectively. On multivariable analysis, alpha-feto protein (HR1.97, 95%CI 1.42-2.72), neutrophil-to-lymphocyte ratio (HR1.74, 95%CI 1.28-2.38), albumin-bilirubin grade (HR1.66, 95%CI 1.21-2.28), and imaging tumor burden score (HR1.25, 95%CI 1.12-1.40) were associated with OS. The c-index in the Eastern test and Western validation cohorts were 0.69 and 0.67, respectively. Notably, mFIBA score outperformed previous HCC staging systems. 5-year OS incrementally decreased with an increase in mFIBA. On multivariable Cox regression analysis, the mFIBA score was associated with worse OS (HR1.18, 95%CI 1.13-1.23) and higher risk of recurrence (HR1.16, 95%CI 1.11-1.20). An easy-to-use calculator of the mFIBA score was made available online (https://yutaka-endo.shinyapps.io/mFIBA_score/).

DISCUSSION

The online mFIBA calculator may help surgeons with clinical decision-making to individualize perioperative treatment strategies for patients undergoing resection of HCC.

摘要

背景

肝细胞癌 (HCC) 的术前预测评分可帮助对接受切除术的患者进行分层,以评估其与长期预后的关系,并制定治疗策略。

方法

从一个国际多机构数据库中确定了 2000 年至 2020 年间接受根治性肝切除术治疗 HCC 的患者。使用东方队列开发了一个风险评分 (mFIBA),然后使用西方队列对其进行验证。

结果

在 957 例患者中,分别有 443 例和 514 例患者来自东方队列和西方队列。多变量分析显示,甲胎蛋白 (HR1.97, 95%CI 1.42-2.72)、中性粒细胞与淋巴细胞比值 (HR1.74, 95%CI 1.28-2.38)、白蛋白-胆红素分级 (HR1.66, 95%CI 1.21-2.28) 和影像学肿瘤负荷评分 (HR1.25, 95%CI 1.12-1.40) 与 OS 相关。在东方测试和西方验证队列中的 C 指数分别为 0.69 和 0.67。值得注意的是,mFIBA 评分优于以前的 HCC 分期系统。mFIBA 评分越高,5 年 OS 逐渐降低。多变量 Cox 回归分析显示,mFIBA 评分与较差的 OS (HR1.18, 95%CI 1.13-1.23) 和更高的复发风险 (HR1.16, 95%CI 1.11-1.20) 相关。mFIBA 评分的在线计算器已在网上提供 (https://yutaka-endo.shinyapps.io/mFIBA_score/)。

讨论

在线 mFIBA 计算器可以帮助外科医生进行临床决策,为接受 HCC 切除术的患者制定个体化的围手术期治疗策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验